| 摘要 |
New DNA segment (s) contg. no more than 1200 nucleotide base pairs includes a sequence defining a structural gene encoding human tissue factor heavy chain protein (huTFh) (I). The aminoacid sequence of (I) is defined. Also claimed is a recombinant DNA molecule comprising a vector operatively linked to (S). Human tissue factor binding site polypeptide analogues (II) with 50 aminoacid residues and including a sequence VNQVYTVQIST (a) or LYYWKSSSSBKKT (b) are also new. The following (II) are specifically claimed: H-EPKP-(a)-KSGDWKSKC-OH (IIa), H-VFGKDLIYTL-(b)-OH (IIG), H-SSSGKKTAKTNTNEFLIDVDKGENYCFSV-OH (IIc) H-SGTTNTVAAYNLTWKSTNFKTILEWEPKPV-OH (IId), H-TKSGDWKSKCFYTTDTECDLTDEIVKDVKQTY-OH (IIe) H-KSGDWKSKC-OH (IIf), H-LARVFSYPAGNVESTGSA BEPLYENSPEFTPYLC-OH (IIg), H-YENSPEFTPYLETNLBQ PTIQSFEQVGTKV-OH (IIh), and H-QAVIPSRTV NRKSTDSPVEC-OH (IIi) Also claimed are: (1) antibodies which immunoreact with (I), (IIa)-(IIi) but not with a polypeptide with sequence 204-226 of (I); (2) antibody secreting hybridomas TF8-5G9, TF9-10H10, TF9-6B4 and TF9-5B7; (3) various uses of the novel antibodies; and (4) diagnostic kits. #CMT#USE/ADVANTAGE : #/CMT# The antibodies may be used in immunoassays for detection of (I). Hybridoma TF9-10H10 antibodies linked to an in vivo detecting means may be used for in vivo detection of thrombi. Hybridoma TF8-5G9 and TF9-6B4 antibodies may be used to neutralise the ability of huTF to bind coagulation factor VII/VIIa in vivo. Polypeptides (IIa)-(IIc) may be used to inhibit the binding of huTF to cogulation factor VII/VIIa in vivo. |
